Katherine L. Nathanson, MD
Pearl Basser Professor of BRCA-related Research, Perelman School of Medicine
Deputy Director, Abramson Cancer Center
University of Pennsylvania
We are always looking for qualified and enthusiastic applicants interested in joining our lab. In particular, individuals seeking opportunities at the postdoctoral level are encouraged to apply. Please click here for the details.
Lab in the News
Penn Medicine Researchers Receive $5.4 million Grant to Find Genetic Drivers of Testicular Cancer
October 28, 2020
The international hunt to find more genetic risk markers for testicular cancer is expanding. A team of researchers led by Katherine L. Nathanson, MD, deputy director of the Abramson Cancer Center and the Pearl Basser Professor for BRCA-Related Research in the Perelman School of Medicine at the University of Pennsylvania, was recently awarded $5.4 million over five years from the National Institutes of Health to continue the long-standing genomics work of the TEsticular CAncer Consortium (TECAC).
The project "Randomized trial of universal vs. guideline-directed germline testing among young adults with cancer" was awarded through the Cancer Moonshot Funding mechanism.
Deputy Director of Penn’s Abramson Cancer Center Receives $3 Million Grant from The Gray Foundation
July 24, 2019
PHILADELPHIA – Katherine L. Nathanson, MD, deputy director of the Abramson Cancer Center at the University of Pennsylvania and the Pearl Basser Professor for BRCA-Related Research in Penn’s Perelman School of Medicine, has been awarded a $3 million research grant from the Gray Foundation. This new Team Science Grant, titled the "Determinants of immune activity and molecular features in BRCA1/2 mutation carriers," will support Nathanson and her team as they study new approaches to understanding immune function both in healthy BRCA mutation carriers and BRCA-related cancers.
Katherine L. Nathanson, MD, Named Inaugural Pearl Basser Professor for BRCA-Related Research – PR News
April 12, 2019
A new gift to support the Basser Center for BRCA at the University of Pennsylvania’s Abramson Cancer Center (ACC) established and endowed the Pearl Basser Professorship for BRCA-Related Research. Katherine L. Nathanson, MD, deputy director of the Abramson Cancer Center and director of genetics at the Basser Center, has been appointed the inaugural chair holder.
NatureRevClinOncol: Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors
Jan 31, 2019
Inherited CHEK2 mutations are high-risk drivers of susceptibility to testicular germ cell tumours and might be informative for the clinical cancer-risk management of mutation carriers and their at-risk family members: https://jamanetwork.com/journals/jamaoncology/fullarticle/2722624 …
Beyond BRCA: Examining Links between Breast Cancer, Second Primary Cancer and Inherited Genetic Mutations
May 31, 2018
The study from the Basser Center for BRCA in the Abramson Cancer Center of the University of Pennsylvania also investigated the use of polygenic risk scores – which have recently been added to some commercial clinical multiplex genetic testing panels. Kara N. Maxwell, MD, PhD, an instructor of Hematology-Oncology and the study’s lead author, will present the findings at the 2018 American Society of Clinical Oncology Annual Meeting in Chicago (Abstract #1503). The team – led by Susan M. Domchek, MD, executive director of the Basser Center for BRCA, and Katherine L. Nathanson, MD, deputy director of the Abramson Cancer Center, specifically looked at patients who did not have a BRCA1/2 mutation and tested them for a panel of 15 different genetic mutations.
Penn Study Finds Relationship between PTEN Loss, Potential for Immune Response in BRCA 1/2-Deficient Ovarian Cancer
April 13, 2018
“PTEN is a genomic marker we already routinely measure, and based on published data we wanted to know if we could use it to predict which BRCA1/2 mutated tumors are likely to respond to checkpoint inhibitors and which are not,” said the study’s senior author Katherine L. Nathanson, MD, deputy director of the Abramson Cancer Center and director of Genetics at the Basser Center for BRCA.
Retention of One Normal Version of BRCA Gene in Breast and Ovarian Cancers Influences Patient Survival, According to Penn-led Study
August 22, 2017
There are many reasons patients may be resistant to treatment — the immune system, the complex landscape of a tumor, or a patient’s own genes can all play a role. Without explicitly looking for it, the Penn team found another mechanism of resistance to a standard treatment for patients with BRCA-associated cancers. “Our primary question was not aimed at evaluating resistance to therapy, but we did end up there,” said senior author Katherine Nathanson, MD, deputy director of the Abramson Cancer Center, and director of Genetics at the Basser Center for BRCA.
An analysis of data from five major studies of testicular cancer has identified new genetic locations that could be susceptible to inherited testicular germ cell tumors. The findings, which researchers call a success story for genome mapping, could help doctors understand which men are at the highest risk of developing the disease and signal them to screen those patients. Researchers from The international TEsticular CAncer Consortium (TECAC), led by Katherine L. Nathanson, MD, a professor of Translational Medicine and Human Genetics at the Perelman School of Medicine at the University of Pennsylvania and a member of Penn’s Abramson Cancer Center, worked with multiple institutions to perform the analysis. The findings were published today in Nature Genetics.
Analyzing genetic data of 173 patients from The Cancer Genome Atlas, researchers, including senior author Katherine Nathanson, MD, a professor in the division of Translational Medicine and Human Genetics at the Perelman School of Medicine at the University of Pennsylvania and associate director for Population Science at Penn’s Abramson Cancer Center, identified CSDE1 and fusion genes in MAML3 as drivers of the disease, both a first for any cancer type. The researchers also classified PCC/PGL into four distinct subtypes, each driven by mutations in distinct biological pathways, two of which are novel.